Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.69 |
| ▸ | MAOA | P21397 | 6/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | SDHA | P31040 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CALML3 | P27482 | 1/20 | 0.69 |
| ▸ | F10 | P00742 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336215 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL76846 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL29439547 | 1.00 | MAOB (0.69) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338391 | 0.94 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338393 | 0.94 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3523994 | 0.91 | F10 (0.59) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3523989 | 0.91 | F10 (0.59) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12176864 | 0.89 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL3525075 | 0.89 | F10 (0.58) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL13404010 | 0.89 | F10 (0.58) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745028-A2 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-24 | — | — | EP | claimed |
| WO-2006110155-A1 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-10-19 | — | — | WO | claimed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | claimed |
| CN-119912441-A | Novel oxazolidinone compound and anti-infection application thereof | 安徽医科大学第一附属医院 | 2025-05-02 | — | — | CN | disclosed |
| EP-2917189-B1 | PROCESS FOR MAKING LINEZOLID | SYNTHON BV (NL) | 2016-08-17 | — | — | EP | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9012631-B2 | 1,3-oxazolidine-2-one-like compound, preparation method and uses thereof | YABANG PHARMACEUTICAL CO., LTD (CN) | 2015-04-21 | — | — | US | disclosed |
| US-20140171640-A1 | 1,3-OXAZOLIDINE-2-ONE-LIKE COMPOUND, PREPARATION METHOD AND USES THEREOF | YABANG PHARMACEUTICAL CO., LTD (CN) | 2014-06-19 | — | — | US | disclosed |
| WO-2014071990-A1 | PROCESS FOR MAKING LINEZOLID | SYNTHON BV (NL) | 2014-05-15 | — | — | WO | disclosed |
| EP-1745028-A2 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006110155-A1 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-10-19 | — | — | WO | disclosed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | F9, Q6ZSR9, TBCD | MAOB 2551/4885MAOA 1756/4885PTGS1 4164/4885 |
| US-20140171640-A1 | 1,3-OXAZOLIDINE-2-ONE-LIKE COMPOUND, PREPARATION METHOD AND USES THEREOF | OXA1L, CYP2C9, CYP1B1 | MAOB 493/4885MAOA 1038/4885PTGS1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.